Wellness for Life Center AmeriSciences Blog - Omega 3 Fatty Acids

Fish oil in the treatment of dyslipidemia.

nospam@example.com (Sultan H. Rahaman, M.D.) — Thu, 06 Mar 2008 05:40:46 -0800

Curr Opin Endocrinol Diabetes Obes. 2008 Apr;15(2):167-74.

Fish oil in the treatment of dyslipidemia.

Division of Endocrinology and Metabolism, University of Miami Miller School of Medicine, Miami, Florida 33136, USA. rgoldber@med.miami.edu

PURPOSE OF REVIEW: The recent availability of a concentrated prescription omega-3 fatty acid preparation provides physicians with an additional anti-dyslipidemic agent at a time when limitations of statin therapy in dyslipidemic high-risk patients are recognized. This review examines the evidence supporting the use of omega-3 fatty acid treatment in dyslipidemic states. RECENT FINDINGS: There is now considerable evidence that omega-3 fatty acid treatment at the prescription strength of 4 g/day effectively and safely lowers triglyceride levels and increases low-density lipoprotein size, as well as affecting high-density lipoprotein metabolism. Similar effects have been noted in patients treated with statins, and add-on prescription omega-3 fatty acid therapy significantly increases the proportion of statin-treated dyslipidemic patients reaching their non-high-density lipoprotein cholesterol goals. In addition to past studies showing a cardioprotective effect of low-dose omega-3 fatty acid treatment against sudden death, a recent controlled clinical trial showed that 1.8 g of omega-3 fatty acid in statin-treated patients reduced major coronary events by 19% compared with statin plus placebo treatment. SUMMARY: Omega-3 fatty acid treatment should be considered in patients with severe hypertriglyceridemia as well as in high-risk patients with an atherogenic lipoprotein phenotype.

-------------------------------------------------------------------

I recommend AmeriSciences Omega Max for Dyslipidemia.

http://www.wellnessforlifecenter.org/omega_max.shtml

Omega3 Fatty acids for cardioprotection.

nospam@example.com (Sultan H. Rahaman, M.D.) — Thu, 06 Mar 2008 05:36:50 -0800

Mayo Clin Proc. 2008 Mar;83(3):324-32.

Omega3 Fatty acids for cardioprotection.

Lee JH, O'Keefe JH, Lavie CJ, Marchioli R, Harris WS.

Address correspondence to James H. O'Keefe, MD, 4330 Wornall Rd, Ste 2000, Kansas City, MO 64111 (jhokeefe@cc-pc.com).

The most compelling evidence for the cardiovascular benefit provided by omega-3 fatty acids comes from 3 large controlled trials of 32,000 participants randomized to receive omega-3 fatty acid supplements containing docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) or to act as controls. These trials showed reductions in cardiovascular events of 19% to 45%. These findings suggest that intake of omega-3 fatty acids, whether from dietary sources or fish oil supplements, should be increased, especially in those with or at risk for coronary artery disease. Patients should consume both DHA and EPA. The target DHA and EPA consumption levels are about 1 g/d for those with known coronary artery disease and at least 500 mg/d for those without disease. Patients with hypertriglyceridemia benefit from treatment with 3 to 4 g/d of DHA and EPA, a dosage that lowers triglyceride levels by 20% to 50%. Although 2 meals of oily fish per week can provide 400 to 500 mg/d of DHA and EPA, secondary prevention patients and those with hypertriglyceridemia must use fish oil supplements if they are to reach 1 g/d and 3 to 4 g/d of DHA and EPA, respectively. Combination therapy with omega-3 fatty acids and a statin is a safe and effective way to improve lipid levels and cardiovascular prognosis beyond the benefits provided by statin therapy alone. Blood DHA and EPA levels could one day be used to identify patients with deficient levels and to individualize therapeutic recommendations.

--------------------------------------------------------------------------

I recommend AmeriSciences Omega Max for Cardioprotection.

http://www.wellnessforlifecenter.org/omega_max.shtml

Heart attack victims to be given omega 3 fish oil

nospam@example.com (Sultan H. Rahaman, M.D.) — Thu, 24 May 2007 09:32:31 -0700

A very interesting article that I read today. It demonstrates the potential for Omega 3 fatty acids to prevent cardiac problems and complications. You can get pharmaceutical quality Omega Max which I use myself and recommend for my patients at: www.AmeriSciencesProducts.com

Sultan Rahaman, M.D.

http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2007/05/23/nomega23.xml

Heart attack victims to be given omega 3

By Nic Fleming, Medical Correspondent

Last Updated: 1:28am BST 23/05/2007

Tens of thousands of heart attack victims are to be prescribed fish oil supplements under guidelines to be published today.

Doctors will tell heart patients to eat at least two portions of oily fish per week or take omega 3 fatty acid tablets for up to four years to reduce the risks of a second attack.

Previous research has suggested that eating oily fish or taking the supplements has a range of health benefits including reduced risk of cardiovascular disease and stroke, better immune system functioning, and improved behaviour in primary school age children.

A clinical trial found daily 1g doses of highly concentrated omega 3 within three months of a heart attack cut the risk of a patient later dying suddenly by 45 per cent.

The recommendation, published by the National Institute for Health and Clinical Excellence (Nice), is part of wide-ranging advice designed to reduce the risks of a secondary attack among the 160,000 people who survive a first heart attack each year.

Patients will be told to follow a Mediterranean diet, high in fruit, vegetables, grains, olive oil and fish.

Doctors will be told to only prescribe the supplements to those who "will not tolerate" a change of diet and those who have had an attack within the previous three months. The diet, two to four portions of oily fish a week, should consist of 7g of omega 3 fatty acids.

Nice estimates that one in five - around 40,000 - patients will be prescribed the pills at an initial annual cost of £7 million to the NHS. Omega 3 and other fatty acids play a key role in maintaining the structure of cell membranes and are important in regulating blood clotting, body temperature, blood pressure, reproduction and the immune system.

The richest sources of omega 3 are oily fish, particularly mackerel, herring, salmon, fresh tuna and trout.

Almost 840,000 men and 400,000 women in the UK have a heart attack at some point in their lives, with around 70,000 dying each year.

Patients will also be advised against taking vitamin A supplements as some research has suggested that it may increase the risk of cardiovascular death in some patients.

Nice experts found no evidence to support the taking of vitamin E, C or folic acid to reduce heart attack risk.

Doctors will continue to advise heart attack sufferers to give up smoking, maintain a healthy weight, reduce alcohol intake and to exercise for 20 to 30 minutes a day.

Nice has, however, resisted calls for omega 3 supplements to be recommended for patients who have had first heart attacks more than three months earlier.

Professor Gene Feder, chairman of the committee that developed the guidance, said Nice was not suggesting that other heart attack victims stop taking fish oil supplements, but that based on the available research "what we feel confident about is that three-month window".

Dr Gill Leng, Nice implementation systems director, said: "Its [the guideline] overall aim is to provide the growing number of people who now survive a heart attack with the good quality systematic care that is essential to improving long-term outcomes and quality of life."

Information appearing on telegraph.co.uk is the copyright of Telegraph Media Group Limited and must not be reproduced in any medium without licence. For the full copyright statement see Copyright

Omega-3 fish oil can help children suffering with ADHD symptoms.

nospam@example.com (Sultan H. Rahaman, M.D.) — Wed, 18 Apr 2007 15:52:49 -0700

Omega-3 fish oil can help children suffering from attention deficit hyperactivity disorder (ADHD) symptoms, a new study suggests.

Results from "the largest, clinical-based omega-3 and omega-6 trial of its kind" bolstered views that fatty acids relieve aspects of the condition.

The tests were undertaken by the University of South Australia and an Australian government research body. They involved 132 children aged between seven and 12 with ADHD symptoms and the active fatty acid used was Equazen's eye q supplement.

For 15 weeks, during the first half of the test, children were split into three groups.

One took eye q, the second took eye q and a multi-vitamin/mineral supplement, while the third took placebo palm oil capsules. All children were then given eye q and the multivitamins/minerals.

At the end of the 30-week-long trial, almost half of the children taking eye q for the whole study saw "significant" reductions in ADHD symptoms of inattention, hyperactivity and impulsivity, researchers said.

After the placebo group switched to the combined oil supplement for 15 weeks, they showed significant improvements in parent behaviour ratings and attention span.

The original eye q group continued to show improvements after an additional 15 weeks of taking the combined oil supplement in cognitive problems, inattention, restlessness, impulsivity and hyperactivity.

Philip Calder, professor of nutritional immunology at the University of Southampton added: "The results of this latest trial add to the growing body of evidence showing that children with attention problems can benefit from increased intake of certain fatty acids."

The new trial results are published in this month's Journal of Developmental and Behavioural Paediatrics.

------------------------------------------------------------------------------------------------------------------------------

Get Pharmaceutical Quality AmeriSciences Omega Max: www.AmeriSciencesProducts.com

http://www.channel4.com/news/articles/society/health/omega3+boost+for+adhd+sufferers/437767

These news feeds are provided by an independent third party and Channel 4 is not responsible or liable to you for the same.

Deficits in the Omega-3 Fatty Acid in Patients with Major Depressive Disorder

nospam@example.com (Sultan H. Rahaman, M.D.) — Tue, 26 Dec 2006 12:51:52 -0800

I recommend AmeriSciences Omega Max for Depression. Here is an abstract below supporting its use for Depression.

Sultan H. Rahaman, M.D.President
Wellness for Life Center, Inc.www.wellnessforlifecenter.org
info@wellnessforlifecenter.org

Biol Psychiatry. 2006 Dec 21; [Epub ahead of print]

Selective Deficits in the Omega-3 Fatty Acid Docosahexaenoic Acid in the Postmortem Orbitofrontal Cortex of Patients with Major Depressive Disorder.

Department of Psychiatry, University of Cincinnati College of Medicine.

BACKGROUND: Epidemiological surveys and peripheral tissue (red blood cells/plasma) fatty acid composition studies suggest that omega-3 fatty acid deficiency is associated with major depressive disorder (MDD) and suicide. It was hypothesized that patients with MDD would exhibit lower frontal cortical concentrations of docosahexaenoic acid (DHA), the principal omega-3 fatty acid in brain, relative to normal controls.

METHODS: We determined the total fatty acid composition of postmortem orbitofrontal cortex (Brodmann's Area 10) from patients with DSM-IV-defined MDD (n = 15) and age-matched normal controls (n = 27) by gas chromatography.

RESULTS: After correction for multiple comparisons, the omega-3 fatty acid DHA was the only fatty acid that was significantly different (-22%) in the postmortem orbitofrontal cortex of MDD patients relative to normal controls. Deficits in DHA concentrations were greater in female MDD patients (-32%) than in male MDD patients (-16%), and could not be wholly attributed to lifestyle factors or postmortem tissue variables.

CONCLUSIONS: These results demonstrate a selective deficit in the omega-3 fatty acid DHA in the orbitofrontal cortex of patients with MDD. This finding adds to a growing body of evidence implicating omega-3 fatty acid deficiency as well as the orbitofrontal cortex in the pathophysiology and potentially pathogenesis of MDD.

PMID: 17188654 [PubMed - as supplied by publisher]

Purchase AmeriSciences Omega Max at: www.amerisciencesproducts.com